Cystic fibrosis and nutrition: Linking phospholipids and essential fatty acids with thiol metabolism

Annual Review of Nutrition

Volumn 28, Issue , 2008, Pages 55-72

  Innis, Sheila M ^a   Davidson, A George F ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Arachidonic acid; Choline; Docosahexaenoic acid; Glutathione; Linoleic acid; Oxidative stress; Redox balance

Indexed keywords

ACYL COENZYME A DESATURASE; ARACHIDONIC ACID; CHOLINE; CYTOKINE; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; GLUTATHIONE; GLUTATHIONE DISULFIDE; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LINOLEIC ACID; LINOLENIC ACID; LIPOXYGENASE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; PHOSPHOLIPID; S ADENOSYLMETHIONINE; THIOL; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CAUCASIAN; CYSTIC FIBROSIS; DIGESTION; FATTY ACID DESATURATION; GENE MUTATION; GLUTATHIONE METABOLISM; HUMAN; LIPID ABSORPTION; METABOLISM; NUTRITION; OXIDATIVE STRESS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; REVIEW;

CYSTIC FIBROSIS; EPITHELIAL CELLS; FATTY ACIDS, ESSENTIAL; GENE EXPRESSION; HUMANS; LIPID METABOLISM; MUTATION; PHOSPHOLIPIDS;

EID: 50949127396     PISSN: 01999885     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.nutr.27.061406.093625     Document Type: Review

References (137)

1. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ. 1991. Generation of cAMP-activated chloride currents by expression of CFTR. Science 251:679-82
2. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutièrrez JP, et al. 1997. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 156:1197-204
3. Ballatori N, Hammond CL, Cunningham JB, Krance SM, Marchan R. 2005. Molecular mechanisms of reduced glutathione transport: role ofthe MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 204:238-55
4. Banerjee R, Zou CG. 2005. Redox regulation and reaction mechanism of human cystethione-beta-synthase: a PLP-dependent hemesensor protein. Arch. Biochem. Biophys. 433:144-56
5. Barraclough M, Taylor CJ. 1996. Twenty-four-hour ambulatory gastric and duodenal pH profiles in cystic fibrosis: effect of duodenal hyperacidity on pancreatic enzyme function and fat absorption. J. Pediatr. Gastroenterol. Nutr. 23:45-50
6. Bear CE, Li CH, Kartner N, Bridges RJ, Jensen TJ, et al. 1992. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 68:809-18
7. Beharry S, Ackerley C, Corey M, Kent G, Heng YM, et al. 2007. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 292 G839-48
8. Belton O, Fitzgerald DJ. 2003. Cyclooxygenase isoforms and atherosclerosis. Expert Rev. Mol. Med. 5:1-18
9. Benabdeslam H, Garcia I, Bellon G, Gilly R, Revol A. 1998. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. Am. J. Clin. Nutr. 57:912-18
10. Bhura-Bandali FN, Suh M, Man SF, Clandinin MT. 2000. The delta F508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells. J. Nutr. 130:2870-75
11. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, et al. 1995. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 151:1075-82
12. Bradbury N. 1999. Intracellular CFTR: localization and function. Physiol. Res. 79:S175-91
13. Cantlin AM, Hubbard RC, Crystal RG. 1989. Glutathione deficiency in epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Resp. Dis. 139:370-72
14. Carey MC, Hernell O. 1992. Digestion and absorption of fat. Semin. Gastrointest. Dis. 3:189-208
15. Carlstedt-Duke J, Bronnegard M, Strandvik B. 1986. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc. Natl. Acad. Sci. USA 83:9202-6
16. Carroccio A, Pardo F, Montalto G, Iapichino L, Soresi M, et al. 1992. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis. Dig. Dis. Sci. 37:1441-46
17. Cawood AL, Carroll MP, Wooton SA, Calder PC. 2005. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr. Opin. Clin. Nutr. Metab. 8:153-59
18. Chen A, Innis S. 2004. Assessment of phospholipid malabsorption by quantification of fecal phospholipid. J. Pediatr. Gastroenterol. Nutr. 39:85-91
19. Chen AH, Innis SM, Davidson AG, James SJ. 2005. Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am. J. Clin. Nutr. 81:686-91
20. Chen L, Patel RP, Teng X, Bosworth CA, Lancaster JR, Matalon S. 2006. Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitroglutathione. J. Biol. Chem. 281:9190-99
21. Christophe A, Robberecht E, Baets F, Franckx H. 1992. Increase of long chain omega-3 fatty acids in major serum lipid classes of patients with cystic fibrosis. Ann. Nutr. Metab. 36:304-12
22. Christophe A, Robberecht E, Franckx H, De Baets F, van de PM. 1994. Effect of administration of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis. Ann. Nutr. Metab. 38:40-47
23. Clandinin MT, Zuberbuhler P, Brown NE, Kielo ES, Goh YK. 1995. Fatty acid pool size in plasma lipoprotein fractions of cystic fibrosis patients. Am. J. Clin. Nutr. 62:1268-75
24. Colombo C, Battezzati PM, Strazzabosco M, Podda M. 1998. Liver and biliary problems in cystic fibrosis. Semin. Liver Dis. 18:227-35
25. Colombo C, Bennato V, Costantini D, Valmarana L, Dacco V, et al. 2006. Dietary and circulating polyunsaturated fatty acids in cystic fibrosis: Are they related to clinical outcome? J. Pediatr. Gastroenterol. 43:660-65
26. Cystic Fibrosis Foundation Consensus Conference. 2002. Concepts in Care: Pediatric Nutrition for Patients with Cystic Fibrosis. Bethesda, MD: Cystic Fibrosis Found.
27. da Costa KA, Niculescu MD, Craciunescu CN, Fischer LM, Zeisel SH. 2006. Choline deficiency increases lymphocyte apoptosis and DNA damage in humans. Am. J. Clin. Nutr. 84:88-94
28. Dalzell AM, Freestone NS, Billington D, Heaf DP. 1990. Small intestinal permeability and orocaecal transit time in cystic fibrosis. Arch. Dis. Child. 65:585-88
29. Davidson AGF. 2000. Gastrointestinal disease in cystic fibrosis. In Cystic Fibrosis, ed. ME Hodson, DM Geddeson, pp. 261-88. London: Arnold
30. Dean TP, Dai Y, Shute JK, Church MK, Warner JO. 1993. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum and sera of children with cystic fibrosis. Pediatr. Res. 34:159-61
31. Depeint F, Bruce WR, Shangrai N, Mehta R. 2006. Mitochondrial function and toxicity: the role of the B vitamins on the one-carbon transfer pathways. Chem. Biol. Interact. 163:113-32
32. De Rose V. 2002. Mechanisms and markers of airway inflammation in cystic fibrosis. Eur. Resp. J. 19:333-40
33. De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. 2003. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J. Parent. Enteral. Nutr. 27:52-57
34. Dodge JA, Turck D. 2006. Cystic fibrosis: nutritional consequences and management. Best Pract. Res. Clin. Gastroenterol. 20:531-46
35. Duthie A, Doherty DG, Williams C, Scott-Jupp R, Warner JO, et al. 1992. Genotype analysis for delta F508, G551D, and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology 15:660-64
36. - channels by protein kinase A corrected by insertion of CFTR. Nature 358:581-84
37. Farrell PM, Mischler EH, Engle MJ, Brown DJ, Lau SM. 1985. Fatty acid abnormalities in cystic fibrosis. Pediatr. Res. 19:104-9
38. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, et al. 2004. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 350:560-69
39. (-/-) mice. Proc. Natl. Acad. Sci. USA 96:13995-4000
40. -/- mice and the effect of docosahexaenoic acid. J. Appl. Physiol. 92:2169-76
41. Freye HB, Kurtz SM, Spock A, Capp MP. 1964. Light and electron microscopic examination of the small bowel of children with cystic fibrosis. J. Pediatr. 64:575-79
42. Friesen RW, Novak EM, Hasman D, Innis SM. 2007. Relationship of dimethylglycine choline and betaine with oxoproline in plasma of pregnant women and their newborn infants. J. Nutr. 137:2641-46
43. Gabriel SE, Clarke LL, Boucher RC, Stutts MJ. 1993. CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 363:263-68
44. Gao L, Kim KJ, Yankaskas JR, Forman HJ. 1999. Abnormal glutathionine transport in cystic fibrosis airway epithelia. Am. J. Physiol. 277:L113-18
45. Gibson RA, Yeubner JK, Haines K, Cooper DM, Davidson GP. 1986. Relationship between pulmonary function and plasma fatty acids in cystic fibrosis patients. J. Pediatr. Gastroenterol. Nutr. 5:408-15
46. Gottlieb RA, Dosanjh A. 1996. Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis. Proc. Natl. Acad. Sci. USA 93:3587-91
47. Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP. 2005. Compartmental modelling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses. J. Lipid Res. 46:1474-83
48. Greally P, Hissein MJ, Sampson AP, Price JF. 1993. Sputum TNF alpha and leukotriene concentrations in cystic fibrosis. Arch. Dis. Child. 148:389-92
49. Gronowitz E, Lorentzon M, Ohlsson C, Mellstrom D, Strandvik B. 2007. Docosahexaenoic acid is associated with endosteal circumference in long bones in adult males with cystic fibrosis. Br. J. Nutr. 99:160-67
50. Guggino WB, Banks-Schlegel SP. 2004. Macromolecular interactions and ion transport in cystic fibrosis. Am. J. Respir. Crit. Care Med. 170:815-20
51. Hallberg K, Grzegorczyk A, Larson G, Strandvik B. 1997. Intestinal permeability in cystic fibrosis in relation to genotype. J. Pediatr. Gastroenterol. Nutr. 25:290-95
52. Henderson WRJ, Astley SJ, McCready MM, Kushmerick P, Casey S, et al. 1994. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J. Pediatr. 124:400-8
53. Hudson VM. 2001. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med. 30:1440-61
54. Infante JP, Huszagh VA. 2001. Zellweger syndrome knockout mouse models challenge putative peroxisomal beta-oxidation involvement in docosahexaenoic acid (22;6n-3) biosynthesis. Mol. Genet. Metab. 72:1-7
55. Innis SM. 1991. Essential fatty acids in growth and development. Prog. Lipid Res. 30:39-103
56. Innis SM. 2003. Perinatal biochemistry and physiology of long chain polyunsaturated fatty acids. J. Pediatr. 143:S1-8
57. Innis SM. 2007. Dietary (n-3) fatty acids and brain development. J. Nutr. 137:855-59
58. Innis SM. 2007. Dietary lipids in early development: relevance to obesity, immune and inflammatory disorders. Curr. Opin. Endocrinol. Obes. 14:359-64
59. Innis SM, Davidson AGF, Chen A, Dyer R, Melnyk S, James SJ. 2003. Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J. Pediatrics 143:351-56
60. Innis SM, Davidson AGF, Melnyk S, James SJ. 2007. Choline related supplements improve abnormal plasma methionine-homocysteine metabolites and glutathione status in children with cystic fibrosis. Am. J. Clin. Nutr. 85:702-8
61. Innis SM, Hassman D. 2006. Evidence of choline depletion with reduced betaine and dimethylglycine with increased homocysteine in children with cystic fibrosis. J. Nutr. 136:2226-31
62. Jumpsen JA, Brown NE, Thomson AB, Paul Man SF, Goh YK, et al. 2006. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J. Cyst. Fibros. 5:77-84
63. Kalivianakis M, Minich DM, Bijleveld CM, van Aalderen WM, Stellaard F, et al. 1999. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am. J. Clin. Nutr. 69:127-34
64. Kang JX, Man SF, Brown NE, Labrecque PA, Clandinin MT. 1992. The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells. Biochem. J. 285:725-29
65. Karp CL, Flick KW, Park S, Soffic TM, Greer R, et al. 2004. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5:388-92
66. Karp CL, Flick LM, Yang R, Uddin J, Petasis NA. 2005. Cystic fibrosis and lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 3:263-79
67. Keen C, Olin A-C, Edentoft A, Gronowitz E, Strandvik B. 2007. Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, Pseudomonas infection, and polyunsaturated fatty acids. Chest 13:1857-64
68. Keicher U, Koletzko B, Reinhardt D. 1995. Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur. J. Clin. Invest. 25:915-19
69. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1075-82
70. Kogan I, Ramjeesingh M, Li C, Kidd JF, Wang Y, et al. 2003. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J. 22:1981-89
71. Konstan MW, Berger M. 1997. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr. Pulmonol. 24:137-42
72. 4 is markedly elevated in the epithelial lining fluid of patients with CF. Am. Rev. Respir. Dis. 148:896-901
73. Kronborg G, Hansen MB, Svenson M, Fomsgaard A, Høiby N, Bendtzen K. 1993. Cytokines in sputum and serum from patients with CF and chronic Pseudomanas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr. Pulmonol. 15:292-97
74. Kurlandsky LE, Bennink MR, Webb PM, Ulrich PJ, Baer LJ. 1994. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr. Pulmonol. 18:211-17
75. Lamireau T, Monnereau S, Martin S, Marcolte JE, Winnock M, Alavarez F. 2004. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J. Hepatol. 41:920-25
76. Lands LC, Grey VL, Smountas AA. 1999. Lymphocyte glutathione levels in children with cystic fibrosis. Chest 116:201-5
77. Lawrence R, Sorrell T. 1993. Eicosapentaenoic acid in cystic fibrosis: evidence for a pathogenic role of leukotriene B4. Lancet 342:465-69
78. Lindblad A, Hultkrantz R, Strandvik B. 1992. Bile duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 16:372-81
79. Lindsell P, Hanrahan JW. 1998. Glutathione permeability of CFTR. Am. J. Physiol. Cell. Physiol. 275:C323-26
80. Liou YA, King DJ, Zibrik D, Innis SM. 2007. Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J. Nutr. 137(4):945-52
81. Lloyd-Still JD, Bibus DM, Powers CA, Johnson SB, Holman RT. 1996. Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr. 85:1426-32
82. Lloyd-Still JD, Johnson SB, Holman RT. 1991. Essential fatty acid status and fluidity of plasma phospholipids in cystic fibrosis infants. Am. J. Clin. Nutr. 54:1029-35
83. Lloyd-Still JD, Powers CA, Hoffman DR, Boyd-Trull K, Lester LA, et al. 2006. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 22:36-46
84. Lukacs GL, Chang K, Kartner N, Rotstein OD, Riordan JR, Grinstein S. 1992. The cystic fibrosis transmembrane regulator is present and functional in endosomes. Role as a determinant of endosomal pH. J. Biol. Chem. 267:4568-72
85. + conductance in human colon is defective in cystic fibrosis. Am. J. Physiol. 277:G709-16
86. Maniscalo M, Sofia M, Pelaia G. 2007. Nitric oxide in upper airway inflammatory diseases. Inflamm. Res. 56:58-59
87. McKenna MC, Hubbard VS, Bieri JG. 1985. Linoleic acid absorption from lipid supplements in patients with cystic fibrosis with pancreatic insufficiency and in control subjects. J. Pediatr. Gastroenterol. Nutr. 4:45-51
88. Mickle JE, Cutting GR. 2000. Genotype-phenotype relationships in cystic fibrosis. Med. Clin. North Am. 84:597-607
89. 2+-induced arachidonic acid release by epithelial cells. DNA Cell Biol. 16:749-59
90. Moss RB, Hsu YP, Olds L. 2000. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin. Exp. Immunol. 120:518-25
91. O'Brien S, Mulcahy H, Fenlon H, O'Broin A, Casey M, et al. 1993. Intestinal bile acid malabsorption in cystic fibrosis. Gut 34:1137-41
92. -/- knockout mite. Metabolism 55:1192-200
93. Pacetti D, Malavolta M, Bocci F, Boselli E, Frega NG. 2004. High-performance liquid chromatography/electrospray ionization ion-trap tandem mass spectrometric analysis and quantification of phosphatidylcholine molecular species in the serum of cystic fibrosis subjects supplemented with docosahexaenoic acid. Rapid Commun. Mass Spectrom. 18:2395-400
94. Panchaud A, Sauty A, Kernen Y, Decosterd LA, Buclin T, et al. 2006. Biological effects of a dietary omega 3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomised, crossover placebo-controlled trial. Clin. Nutr. 25:418-27
95. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. 2001. Physiological compartmental amlysis of alpha linolenic acid metabolism in adult humans. J. Lipid Res. 42:1257-65
96. Peretti N, Marcil V, Drouin E, Levy E. 2005. Mechanisms of lipid malabsorption in cystic fibrosis: the impact of essential fatty acids deficiency. Nutr. Metab. 2:11
97. Reid DW, Misso N, Aggarwahl S, Thompson PJ, Walters EH. 2007. Oxidative stress and lipid-derived inflammatory mediators during acute expression of cystic fibrosis. Respirology 12:63-69
98. Reisin IL, Prat AG, Abraham EH, Amara JF, Gregory RJ, et al. 1994. The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel. J. Biol. Chem. 269:20584-91
99. Riordan JR. 1999. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein. Am. J. Genet. 64:1499-504
100. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-73
101. Robinson PJ, Smith AL, Sly PD. 1990. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Dig. Dis. Sci. 35:1299-304
102. Rogiers V, Dab I, Michotte Y, Vercruysse A, Crokaert R, Vis HL. 1984. Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of cystic fibrosis patients (in vitro study). Pediatr. Res. 18:704-9
103. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059-65
104. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, et al. 2001. Early pulmonary infection, inflammation and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonal. 32:356-66
105. Roulet M, Frascarolo P, Rappaz I, Pilet M. 1997. Essential fatty acid deficiency in well-nourished young cystic fibrosis patients. Eur. J. Pediatr. 156:952-56
106. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. 1993. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. 75:2419-24
107. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. 2001. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am. J. Resp. Crit. Care Med. 164:1425-31
108. Sampath H, Ntambi JM. 2005. The fate and intermediary metabolism of stearic acid. Lipids 40:1187-91
109. Scambi C, Guarini P, De Franceshi L, Bambara LM. 2006. Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients? J. Cyst. Fibros. 5:197-99
110. - secretion. J. Physiol. 505:411-23
111. Serhan CN. 2007. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25:101-37
112. Slomiany A, Liau YH, Carter SR, Newman LJ, Slomiany BL. 1985. Mucus glycoprotein fatty acyltransferase in patients with cystic fibrosis: effect on the glycoprotein viscosity. Biochem. Biophys. Res. Commun. 132:299-306
113. Sprecher H, Chen Q, Yin FQ. 1999. Regulation of the biosynthesis of 22:5n-6 and 22:6n-3: complex intracellular process. Lipids 34:S153-56
114. Stead LM, Brosnan JT, Brosnan ME, Vance DE, Jacobs RL. 2006. Is it time to reevaluate methyl balance in humans? Am. J. Clin. Nutr. 83:5-10
115. Strandvik B, Bronnegard M, Gilljam H, Carlstedt-Duke J. 1988. Relation between defective regulation of arachidonic acid release and symptoms in cystic fibrosis. Scand. J. Gastroenterol. Suppl. 143:1-4
116. Strandvik B, Gronowitz E, Enlund F, Martinsson T, Wahlstrom J. 2001. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J. Pediatr. 139:650-55
117. Strandvik B, Svensson E, Seyberth HW. 1996. Prostanoid biosynthesis in patients with cystic fibrosis. Prostaglandins Leukot. Essent. Fatty Acids 55:419-42
118. Thies NH. 1997. The effect of 12 months' treatment with eicosapentaenoic acid in five children with cystic fibrosis. J. Pediatr. Child Health 33:349-51
119. Thompson GN. 1989. Relationships between essential fatty acid levels, pulmonary function and fat absorption in preadolescent cystic fibrosis children with good clinical scores. Eur. J. Pediatr. 148:327-29
120. Ulane MM, Buder JDB, Peri A, Milele L, Ulane RE, Hubbard VS. 1994. Cystic fibrosis and phosphatidylcholine biosyntheis. Clin. Chim. Acta 230:109-16
121. Vawter GF, Shwachman H. 1979. Cystic fibrosis in adults: an autopsy study. Pathol. Ann. 14:357-82
122. Velsor LW, Kariya C, Kachadourian R, Day BJ. 2006. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 35:579-86
123. Vlahcevic ZR, Miller JR, Farrar JT, Swell L. 1971. Kinetics and pool size of primary bile acids in man. Gastroenterology 61:85-90
124. Wagener JS, Kahn TZ, Copenhauer SC, Accurso FJ. 1997. Early inflammation and the development of pulmonary disease in cystic fibrosis. Pediatr. Pulmonal. 16:267-68
125. Walkowiak J, Wilczynski M, Boleslawska I, Krawczynski M, Korzon M, Przyslawski J. 2003. The predominance of omega 6 polyunsaturated fatty acids in cystic fibrosis despite low arachidonic acid levels. Acta Paediatr. 92:1354-55
126. Walters MP, Littlewood JM. 1998. Faecal bile acid and dietary residue excretion in cystic fibrosis: age group variations. J. Pediatr. Gastroenterol. Nutr. 27:296-300
127. Watkins SM, Zhu X, Zeisel SH. 2002. Phosphatidylethanolamine-N- methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J. Nutr. 133:3386-91
128. Werner A, Bongers MEJ, Bijvelds MJ, de Jonge HR, Verkade HJ. 2004. No indicatiors for altered essential fatty acid metabolism in two murine models for cystic fibrosis. J. Lipid Res. 45:2277-86
129. Wesley A, Forstner J, Qureshi R, Mantle M, Forstner G. 1983. Human intestinal mucin in cystic fibrosis. Pediatr. Res. 17:65-69
130. Williams CM, Burdge GC. 2006. Long-chain n-3 PUFA: plant v. marine sources. Proc. Nutr. Soc. 65:42-50
131. Wong LT, Turtle S, Davidson AG. 1982. Secretin pancreozymin stimulation test and confirmation of the diagnosis of cystic fibrosis. Gut 23:744-50
132. Wu G, Fang Y-Z, Yang S, Lupton JR, Turner ND. 2004. Glutathione metabolism and its implications for health. J. Nutr. 134:489-92
133. Zakrzewski JT, Barnes NC, Piper PJ, Costello JF. 1987. Detection of sputum eicosanoids in cystic fibrosis and normal saliva by bioassay and radioimmunoassay. Br. J. Clin. Pharmacol. 23:19-27
134. Zeisel SH. 2006. Choline: critical role during fetal development and dietary requirements in adults. Annu. Rev. Nutr. 26:229-50
135. Zeisel SH, Blusztajn JK. 1994. Choline and human nutrition. Annu. Rev. Nutr. 14:269-96
136. Zeitlin PL. 2006. Is it a Go or NO Go for S-nitrosylation modification-based therapies of cystic fibrosis transmembrane regulator trafficking? Am. Soc. Pharmacol. Exp. Ther. 70:1155-58
137. Zielenski J. 2000. Genotype and phenotype in cystic fibrosis. Respiration 67:117-33